Lepu Biopharma Co., Ltd. (HKG:2157)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
5.60
+0.45 (8.74%)
At close: Mar 27, 2026
Market Cap10.10B +75.3%
Revenue (ttm)1.04B +154.2%
Net Income290.85M
EPS0.17
Shares Out1.80B
PE Ratio33.55
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume32,302,000
Average Volume14,471,250
Open5.16
Previous Close5.15
Day's Range5.02 - 5.64
52-Week Range3.05 - 10.50
Beta-0.24
RSI67.53
Earnings DateMar 25, 2026

About Lepu Biopharma

Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of first-in class and best-in-class drug candidates in anti-tumor targeted therapy and oncology immunotherapy in China and internationally. The company offers PUYOUHENG (Pucotenlimab Injection), a humanized IgG4 mAb against human PD-1 for the treatment of solid tumors and melanoma. It is also developing MRG003 that is in phase III clinical study for treating nasopharyngeal cancer, and head and neck squamous cell carcinoma; and MRG... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 546
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2157
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements